Ponatinib

Last Updated: 09/19/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1368 publications

Prophylactic use of tyrosine kinase inhibitors after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

Prophylactic use of tyrosine kinase inhibitors after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 30, 2026

The anti-leukemia drug ponatinib attenuates NLRP3 inflammasome activation in macrophages.

The anti-leukemia drug ponatinib attenuates NLRP3 inflammasome activation in macrophages.

Journal: Immunobiology
Published: July 13, 2026

Ponatinib in CML and Ph+ ALL: balancing high efficacy with vascular safety.

Ponatinib in CML and Ph+ ALL: balancing high efficacy with vascular safety.

Journal: Postgraduate medicine
Published: July 12, 2026

Ponatinib plus asciminib in myeloid blast-phase CML harboring a phased BCR::ABL1 Y253H/T315I compound mutation: a case report.

Ponatinib plus asciminib in myeloid blast-phase CML harboring a phased BCR::ABL1 Y253H/T315I compound mutation: a case report.

Journal: Frontiers in oncology
Published: July 05, 2026

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 09, 2026

Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.

Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.

Journal: ClinicoEconomics and outcomes research : CEOR
Published: May 30, 2026

Ichthyosiform pityriasis rubra pilaris-like eruption induced by ponatinib, successfully treated with topical vitamin D3 ointment.

Ichthyosiform pityriasis rubra pilaris-like eruption induced by ponatinib, successfully treated with topical vitamin D3 ointment.

Journal: European journal of dermatology : EJD
Published: May 25, 2026

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Journal: Blood reviews
Published: May 19, 2026

Inhibition of Fibroblast Growth Factor Receptor 3 Signaling by Ponatinib Reduces Growth and Cytokine Production of Multiple Myeloma Cells.

Inhibition of Fibroblast Growth Factor Receptor 3 Signaling by Ponatinib Reduces Growth and Cytokine Production of Multiple Myeloma Cells.

Journal: International journal of molecular sciences
Published: May 13, 2026

Dynamics of in vivo immune remodeling in Ph+ all patients receiving frontline ponatinib and blinatumomab therapy.

Dynamics of in vivo immune remodeling in Ph+ all patients receiving frontline ponatinib and blinatumomab therapy.

Journal: Blood cancer journal
Published: May 10, 2026

Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL.

Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 08, 2026

Polymeric rapamycin nanoparticles encapsulating ponatinib cause regression of venous malformations in mice.

Polymeric rapamycin nanoparticles encapsulating ponatinib cause regression of venous malformations in mice.

Journal: Science translational medicine
Published: May 06, 2026
Showing 1-12 of 1,368

Last Updated: 09/19/2026